The FDA has approved Infilbray (venglustat) tablets, the first treatment for neurological symptoms of Type 3 Gaucher disease.
The drug is approved for adults and pediatric patients weighing at least 15 kilograms (approximately 33 pounds), according to a Nov. 18 FDA news release. Infilbray crosses the blood-brain barrier and works as a glucosylceramide synthase inhibitor.
Approval was supported by a randomized, double-blind, multicenter clinical study enrolling 43 patients ages 12 and older. At Week 52, patients treated with Infilbray demonstrated improvement on a measure combining assessments of neurological symptoms compared with patients taking enzyme replacement therapy for nonneurologic manifestations of Type 3 Gaucher disease.
Serious psychiatric risks, including suicidal ideation and behavior, have been reported. Infilbray received orphan drug designation and priority review.
The FDA granted approval to Genzyme Corporation, a Sanofi company.